期刊
CHEMMEDCHEM
卷 16, 期 4, 页码 713-723出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202000742
关键词
angiogenesis; calixarenes; drug design; galectin; metastasis
资金
- Ludwigs-Maximillians-Universitat (LMU) Center for Advanced Study
- Alexander von Humboldt Stiftung
- National Science Foundation [BIR-961477]
- University of Minnesota Medical School
- Minnesota Medical Foundation
The study found that PTX008 has low affinity for Gal-3, but the modified PTX013 has significantly stronger binding. PTX013 also shows stronger binding to Gal-1, while neither interact strongly with Gal-7.
Calix[4]arene PTX008 is an angiostatic agent that inhibits tumor growth in mice by binding to galectin-1, a beta-galactoside-binding lectin. To assess the affinity profile of PTX008 for galectins, we used N-15,H-1 HSQC NMR spectroscopy to show that PTX008 also binds to galectin-3 (Gal-3), albeit more weakly. We identified the contact site for PTX008 on the F-face of the Gal-3 carbohydrate recognition domain. STD NMR revealed that the hydrophobic phenyl ring crown of the calixarene is the binding epitope. With this information, we performed molecular modeling of the complex to assist in improving the rather low affinity of PTX008 for Gal-3. By removing the N-dimethyl alkyl chain amide groups, we produced PTX013 whose reduced alkyl chain length and polar character led to an approximately eightfold stronger binding than PTX008. PTX013 also binds Gal-1 more strongly than PTX008, whereas neither interacts strongly, if at all, with Gal-7. In addition, PTX013, like PTX008, is an allosteric inhibitor of galectin binding to the canonical ligand lactose. This study broadens the scope for galectin targeting by calixarene-based compounds and opens the perspective for selective galectin blocking.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据